OCTOBER 20256EUROPEInnovation in life sciences is moving from isolated breakthroughs to a more integrated path of progress. Across research and biomanufacturing, once-separate disciplines--genomics, biomaterials and computational modeling--are now working together to accelerate discovery and redefine what is possible in medicine.Next-generation DNA technologies are uncovering the architecture of life itself. By decoding entire genomes and translating genetic data into actionable insights, scientists are creating therapies tailored to individual biology rather than broad population trends. These advances are shortening the journey from concept to treatment, guiding drug developers toward more precise and less invasive solutions. At the same time, biodegradable polymers are transforming how therapies are delivered. Engineered to release medication at targeted sites and dissolve safely after use, they combine medical performance with environmental responsibility, reflecting a growing focus on sustainable innovation.Artificial intelligence and computational modeling are further amplifying this shift. By predicting how compounds behave before they enter the lab, AI reduces trial-and-error and compresses traditional discovery timelines from years to months. Driven by these trends, the global drug discovery services market is projected to reach around US $79.7 billion by 2034, growing at a CAGR of approximately 14.1 percent. The recombinant DNA technology market is expected to expand to about US $1.29 trillion by 2033, at a CAGR of around 5.1 percent. Meanwhile, the biodegradable polymer market, valued at US $8.34 billion in 2024, is projected to reach US $20.04 billion by 2031.This magazine features thought leadership articles from Yuri Pashchuk, Associate Chief Nursing Officer at AdventHealth and Leslie Hurst, Associate Vice President and Specialty Pharmacy & PBM Strategy at Baptist Health System, who share insights on how data-driven patient care and integrated pharmacy strategies are transforming clinical outcomes and operational excellence.We also highlight firms transforming forensic and clinical diagnostics. One such company, ANDE, stands out as a global leader in Rapid DNA technology, providing fully automated, portable systems that deliver DNA identification in under two hours, empowering law enforcement to accelerate investigations and bring closure to families. In this edition, featuring leaders redefining drug development solutions, DNA technology and biodegradable polymer development services, we hope you find the right partner to meet your organization's needs.Let us know your thoughts!EDITORIALRapid DNA and Drug Development Driving Precision and Patient CareCopyright © 2025 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com OCTOBER 27 , 2025 , Vol 06, Issue - 28 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.comEditorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersPresley MeadowDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsHenry SmithClara MatthewEUROPE
< Page 5 | Page 7 >